Update in Kaposi sarcoma

Current Opinion in Oncology

Volumn 15, Issue 5, 2003, Pages 379-381

  Noy, Ariela ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Endothelial cells; HHV 8; HIV; Kaposi sarcoma

Indexed keywords

ANGIOGENIC FACTOR; ANTIBODY; ANTIRETROVIRUS AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOKINE; FLAVOPIRIDOL; IM 862; IMATINIB; PLACEBO; PROTEINASE INHIBITOR; RETINOID;

CARCINOGENESIS; CLINICAL TRIAL; ENDOTHELIUM CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; KAPOSI SARCOMA; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY;

HUMANS; SARCOMA, KAPOSI;

EID: 0042332040     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200309000-00006     Document Type: Short Survey

References (30)

1. Scadden DT: AIDS-related malignancies. Annu Rev Med 2003, 54:285-303.
2. Grulich A, Li Y, McDonald AM, et al.: Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001, 15:629-633.
3. Lagunoff M, Bechtel J, Venetsanakos E, et al.: De novo infection and serial transmission of Kaposi's sarcoma-associated herpesvirus in cultured endothelial cells. J Virol 2002, 76:2440-2448.
4. Akula SM, Pramod NP, Want FZ, Chandran B: Integrin alpha3beta1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells. Cell 2002, 108:407-419.
5. Ensoli B, Sturzl M, Monini P: Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Adv Cancer Res 2001, 81:161-200.
6. Sturzl M, Zietz C, Monini P, Ensoli B: Human herpesvirus-8 and Kaposi's sarcoma: relationship with the multistep concept of tumorigenesis. Adv Cancer Res 2001, 81:125-159.
7. Bais C, Santmasso B, Coso O, et al.: G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998, 391:86-89.
8. Yang TY, Chen SC, Leach MW, et al.: Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med 2000, 191:445-454.
9. Barillari G, Ensoli B: Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clin Microbiol Rev 2002, 15:310-326.
10. Toschi E, Barillari G, Sgadari C, et al.: Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Mol Biol Cell 2001, 12:2934-2946.
11. Deregibus MC, Cantaluppi V, Doublier S, et al.: HIV-1-Tat protein activates phosphatidylinositol 3-kinase/AKT-dependent survival pathways in Kaposi's sarcoma cells. J Biol Chem 2002, 277:25195-25202.
12. Demirhan I, Chandra A, Hasselmayer O, et al.: Detection of distinct patterns of anti-tat antibodies in HIV-infected individuals with or without Kaposi's sarcoma. J Acquir Immune Defic Syndr 1999, 22:364-368.
13. Wang QJ, Jenkins FJ, Jacobsen LP, et al.: Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins. Blood 2001, 97:2366-2373.
14. Sirianni MC, Vincenzi L, Topino S, et al.: NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur J Immunol 2002, 32:2711-2720.
15. Poole LJ, Yu Y, Kim PS, et al.: Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus. J Virol 2002, 76:3395-3420.
16. Moses AV, Jarvis MA, Raggo C, et al.: Kaposi's sarcoma-associated herpes-virus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol 2002, 76:8383-8399.
17. Cornelissen M, Van Der Kuyl AC, Van Den Burg R, et al.: Gene expression profile of AIDS-related Kaposi's sarcoma. BMC Cancer 2003, 3:7.
18. Gill J, Bourboulia D, Wilkinson J, et al.: Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002, 31:384-390.
19. Noy A, Gill P, Scadden D, et al.: Angiogenesis inhibitor IM862 is ineffective against AIDS-KS in a randomized, placebo, controlled trial. [Abstract]. 6th International Conference on Malignancies in AIDS and Other Immunodeficiencies, 2002.
20. Wilkinson J, Cope A, Gill J, et al.: Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J Virol 2002, 76:2634-2640.
21. Sgadari C, Barillari G, Toschi E, et al.: HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002, 8:225-232.
22. Pati S, Pelser CB, Dufraine J, et al.: Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 2002, 99:3771-3779.
23. Guo WX, Gill PS, Antakly T: Inhibition of AIDS-Kaposi's sarcoma cell proliferation following retinoic acid receptor activation. Cancer Res 1995, 55:823-829.
24. Tsang KJ, Crowe DL: Retinoic acid and extracellular matrix inhibition of matrix metalloproteinase 9 expression is mediated by the mitogen activated protein kinase pathway. Int J Oncol 2001, 18:369-374.
25. Miles SA, Dezube BJ, Lee JY, et al.: Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 2002, 16:421-429.
26. Aboulafia D, Norris D, Henry D, et al.: 9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial. Arch Dermatol 2003, 139:178-186.
27. Cianfrocca M, Cooley TP, Lee JY, et al.: Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002, 20:153-159.
28. Koon HB, Bubley G, Pantanowitz L, et al.: Imatinab mesylate in AIDS-related Kaposi's sarcoma [Abstract]. ASCO Proceedings, 2003.
29. Senderowicz AM: The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist 2002, 7(Suppl 3):12-19.
30. Krown S: Therapy of AIDS-Associated Kaposi's Sarcoma: Targeting Pathogenetic Mechanisms. Hematol/Oncol Clin North Am 2003, 17:763-783.